Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2020-08-11 Delisting Announcement
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
Delisting Announcement 2020
Delisting Announcement
2020-08-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on an amendment and restatement of the company's bylaws, specifically adding a new forum selection provision for legal disputes. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing announcing a corporate governance change. Therefore, it fits best under Regulatory Filings (RNS). The document length is 6125 characters, which is consistent with a detailed 8-K filing rather than a brief announcement or proxy material.
2020-07-17 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 24, 2020. It reports an amendment to the non-employee director compensation policy by the board of directors, specifically eliminating certain service retainers for committee members. The document includes a reference to an exhibit containing the amended compensation policy. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The content focuses on changes related to board compensation, which falls under management or board information. Therefore, the document is best classified as Board/Management Information (MANG). The document length is 3589 characters, which is consistent with a typical 8-K filing for such announcements, not a full report or earnings release.
2020-06-24 English
FORM 4
Director's Dealing
2020-06-23 English
FORM 4
Director's Dealing
2020-06-23 English
FORM 4
Director's Dealing
2020-06-23 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.